Brett Delahunt
Overview
Explore the profile of Brett Delahunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
5509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Egevad L, Micoli C, Delahunt B, Samaratunga H, Garmo H, Stattin P, et al.
J Clin Pathol
. 2025 Mar;
PMID: 40081884
Reporting of prostate cancer grade has drifted to higher reported grades over the past decades. In prostate cancers diagnosed on needle biopsy of 1 72 112 men reported to The...
2.
Egevad L, Micoli C, Delahunt B, Samaratunga H, Garmo H, Stattin P, et al.
Pathology
. 2025 Feb;
57(3):293-296.
PMID: 39924438
Prostate cancer grade is currently often reported both by Gleason scores and by grouping of the scores into five so-called International Society of Urological Pathology (ISUP) grades (also known as...
3.
Mohanty S, Lobo A, Jha S, Sangoi A, Akgul M, Trpkov K, et al.
Virchows Arch
. 2024 Sep;
485(5):829-840.
PMID: 39287823
Oncocytic renal neoplasms are a major source of diagnostic challenge in genitourinary pathology; however, they are typically nonaggressive in general, raising the question of whether distinguishing different subtypes, including emerging...
4.
Samaratunga H, Delahunt B, Olsson M, Aly M, Egevad L, Yaxley J
Pathology
. 2024 Sep;
56(7):1059-1061.
PMID: 39237382
No abstract available.
5.
Marsland M, Jiang C, Faulkner S, Steigler A, McEwan K, Jobling P, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199567
This study investigated the prognostic value of the chemokine C-C motif ligand 2 (CCL2) and its receptor C-C motif chemokine receptor 2 (CCR2) expression in locally advanced prostate cancer treated...
6.
Bullen J, Nickel B, McCaffery K, Wilt T, Smith J, Boroumand F, et al.
BMJ Open
. 2024 Aug;
14(8):e085947.
PMID: 39122400
Introduction: Many types of prostate cancer present minimal risk to a man's lifespan or well-being, but existing terminology makes it difficult for men to distinguish these from high-risk prostate cancers....
7.
Logan J, Martini C, Sorvina A, Johnson I, Brooks R, Caruso M, et al.
Sci Data
. 2024 Aug;
11(1):852.
PMID: 39117701
The diagnosis of prostate cancer using histopathology is reliant on the accurate interpretation of prostate tissue sections. Current standards rely on the assessment of Haematoxylin and Eosin (H&E) staining, which...
8.
Egevad L, Micoli C, Delahunt B, Samaratunga H, Orrason A, Garmo H, et al.
Virchows Arch
. 2024 Apr;
484(6):995-1003.
PMID: 38683251
A 5-tier grouping of Gleason scores has recently been proposed. Studies have indicated prognostic heterogeneity within these groups. We assessed prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) for men...
9.
Ray Das S, Delahunt B, Lasham A, Li K, Wright D, Print C, et al.
Pathology
. 2024 Apr;
56(4):473-483.
PMID: 38594116
The clinical importance of assessing and combining data on TP53 mutations and isoforms is discussed in this article. It gives a succinct overview of the structural makeup and key biological...
10.
Samaratunga H, Egevad L, Yaxley J, Perry-Keene J, Le Fevre I, Kench J, et al.
Pathology
. 2023 Dec;
56(1):33-38.
PMID: 38071161
Prostate adenocarcinoma is a common malignancy associated with a significant morbidity and mortality. In both prostate biopsies and radical prostatectomy specimens Gleason scoring informs both treatment and outcome prediction. The...